PTX-35

News alerts, weekly reports and conference planners

Company:

Scorpius Holdings

Drug class:

DR3 agonist, T-cell co-stimulation modulator

‹

›

almost2years

PTX-35 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=22, Terminated, Pelican Therapeutics, Inc. | N=36 --> 22 | Trial completion date: Feb 2023 --> Jun 2023 | Active, not recruiting --> Terminated; Absence of immunological response

almost 2 years ago

Enrollment change • Trial completion date • Trial termination • Metastases

PTX-35

almost5years

[VIRTUAL] PTX-35, a potential first-in-class TNFRSF25 agonist, reduced the suppressive activity of regulatory T cells and enhanced CD4+ T cell effector responses, in the presence of tumor antigens, in a murine melanoma model (AACR 2021)

In conclusion, we demonstrate that mPTX-35, in the presence of tumor antigens, resulted in the reprogramming of the Treg cell phenotype, including reduced suppressive activity of Tregs and increased plasticity towards inflammatory Th1 and Th17 cells. PTX-35 has the potential to improve the efficacy of treatment regimens where tumor antigens are released.

almost 5 years ago

Preclinical • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • CD40 (CD40 Molecule) • NRP1 (Neuropilin 1)

IL2RA expression

PTX-35